Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc33090785    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease #MMPMID33090785
  • Macchiagodena M; Pagliai M; Karrenbrock M; Guarnieri G; Iannone F; Procacci P
  • J Chem Theory Comput 2020[Nov]; 16 (11): 7160-7172 PMID33090785show ga
  • In the context of drug-receptor binding affinity calculations using molecular dynamics techniques, we implemented a combination of Hamiltonian replica exchange (HREM) and a novel nonequilibrium alchemical methodology, called virtual double-system single-box, with increased accuracy, precision, and efficiency with respect to the standard nonequilibrium approaches. The method has been applied for the determination of absolute binding free energies of 16 newly designed noncovalent ligands of the main protease (3CL(pro)) of SARS-CoV-2. The core structures of 3CL(pro) ligands were previously identified using a multimodal structure-based ligand design in combination with docking techniques. The calculated binding free energies for four additional ligands with known activity (either for SARS-CoV or SARS-CoV-2 main protease) are also reported. The nature of binding in the 3CL(pro) active site and the involved residues besides the CYS-HYS catalytic dyad have been thoroughly characterized by enhanced sampling simulations of the bound state. We have identified several noncongeneric compounds with predicted low micromolar activity for 3CL(pro) inhibition, which may constitute possible lead compounds for the development of antiviral agents in Covid-19 treatment.
  • |Antiviral Agents/pharmacology/therapeutic use[MESH]
  • |Betacoronavirus/*enzymology[MESH]
  • |COVID-19[MESH]
  • |Coronavirus 3C Proteases[MESH]
  • |Coronavirus Infections/drug therapy/virology[MESH]
  • |Cysteine Endopeptidases/*metabolism[MESH]
  • |Humans[MESH]
  • |Ligands[MESH]
  • |Molecular Docking Simulation[MESH]
  • |Pandemics[MESH]
  • |Pneumonia, Viral/drug therapy/virology[MESH]
  • |Protease Inhibitors/pharmacology/therapeutic use[MESH]
  • |Protein Binding[MESH]
  • |SARS-CoV-2[MESH]
  • |User-Computer Interface[MESH]
  • |Viral Nonstructural Proteins/antagonists & inhibitors/*metabolism[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    7160 11.16 2020